Updates in Parkinson’s disease

A recent study in patients with Parkinson’s disease highlighted the link between visual dysfunction and cognitive decline, as well as greater white matter degeneration. The FDA also approved Gocovri extended-release tablets for patients with PD. Read these and more recent stories below.

Vision linked to cognitive decline, white matter degeneration in Parkinson’s disease

Patients with Parkinson’s disease and visual dysfunction had a higher risk for cognitive impairment and greater white matter degeneration compared with those without visual dysfunction, according to results published in Movement Disorders. Read more.

Gocovri receives FDA approval for second indication in Parkinson’s disease

The FDA approved Gocovri extended-release tablets for patients with Parkinson’s disease, marking the product’s second indication in the disease, according to a press release from Adamas Pharmaceuticals, the drug’s manufacturer. Read more.

Socioeconomic status impacts telehealth use in Parkinson’s disease during COVID-19

The use of telehealth among patients with Parkinson’s disease increased from 9.7% before the COVID-19 pandemic to 63.5% during the pandemic, according to an analysis of more than 1,300 patients published in NJP Parkinson’s Disease. Read more.

Adherence to certain diets linked to later onset of Parkinson’s disease

Following certain diets, including the Mediterranean-DASH Intervention for Neurodegenerative Delay and the Greek Mediterranean diet, correlated with later onset of Parkinson’s disease in a cross-sectional study of patients in Canada. Read more.

Focused ultrasound subthalamotomy improves motor signs in asymmetric Parkinson’s disease

Focused ultrasound subthalamotomy improved motor features in a group of patients with asymmetric signs of Parkinson’s disease, although adverse events were “frequent,” according to results published in The New England Journal of Medicine. Read more.